By Capping Out-Of-Pocket Price, Eli Lilly Could Transform Insulin Market In what could represent a significant transformation of the insulin marketplace, Eli Lilly has announced it will slash the price of two of its insulin products by 70%; Humalog and Humulin. And, the company will cap commercially insured and uninsured patients’ out-of-pocket costs at $35 per month.